 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C6H4K2NO8V |
| Molecular Weight | 347.24 |
| Exact Mass | 346.865 |
| CAS # | 722494-26-0 |
| Appearance | Light yellow to yellow solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results.(2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50: 14 nM (PTEN)[1] |
| ln Vitro | BpV(HOpic) (1 μM) therapy boosted cell division and decreased the rate of apoptosis in MG63 cells treated with cisplatin [3]. Bpv(HOpic) (1 μM) stimulated C2C12 myoblast migration, interacted with PI3K/AKT, and was linked to the MAPK/ERK signaling pathway activation [4]. Like in humans and rodents, BpV(HOpic (1 μM; 48 hours) stimulates the start of follicle growth and development in pigs [5]. Neural axonal development is enhanced by nanocarrier-BpV(HOpic) [2]. |
| ln Vivo | After reperfusion, BpV(HOpic (0.05 mg/kg; ip) ameliorates liver ischemia/reperfusion (I/R) injury in vivo[6]. Mice exposed to BpV (HOpic (200 μg/kg; ip) Injury (IRI) experience worsening renal dysfunction and increased tubular damage[7]. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats are subjected to partial hepatic ischemia[6] Doses: 0.05 mg/kg Route of Administration: Ip injections at the start of reperfusion Experimental Results: Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation. Animal/Disease Models: Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia[7] Doses: 200 μg/ kg Route of Administration: Ip injections 1 h before ischemia and then administers every 6 h after ischemia for 24 hr Experimental Results: Raised the level of serum creatinine and blood serum urea nitrogen. |
| References |
[1]. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004 May 21; 566(1-3): 35-8. [2]. Nanotherapeutics of PTEN Inhibitor with Mesoporous Silica Nanocarrier Effective for Axonal Outgrowth of Adult Neurons. ACS Appl Mater Interfaces. 2016 Jul 27; 8(29): 18741-53. [3]. Silencing of miR-19a-3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN. Oncol Lett. 2019 Jan; 17(1): 414-421. [4]. Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways. J Muscle Res Cell Motil. 2013 May; 34(2): 125-36. [5]. The effect of bpV(HOpic) on in vitro activation of primordial follicles in cultured swine ovarian cortical strips. Reprod Domest Anim. 2019 Aug; 54(8): 1057-1063. [6]. Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury. Liver Transpl. 2011 Apr; 17(4): 474-82. [7]. Pharmacological Inhibition of PTEN Aggravates Acute Kidney Injury. Sci Rep. 2017 Aug 25; 7(1): 9503. |
Solubility Data
| Solubility (In Vitro) |
H2O: 50 mg/mL (143.99 mM) DMSO: 2.89 mg/mL (8.32 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8799 mL | 14.3993 mL | 28.7985 mL | |
| 5 mM | 0.5760 mL | 2.8799 mL | 5.7597 mL | |
| 10 mM | 0.2880 mL | 1.4399 mL | 2.8799 mL |